Cancer of the breast. Endocrine and hormonal therapy.
Additive hormonal therapy remains the treatment of choice for disseminated breast cancer in postmenopausal women. Patients with hormone-dependent tumors receive excellent and long-lasting palliation from alterations in the hormonal milieu. Now that hormone receptor assays are clinically available, responses can be accuratedly predicted in a large percentage of cases. Tables 11--6 is a summary of additive hormonal therapy in postmenopausal patients. Endocrine ablative therapy remains of primary importance in premenopausal women because of the superior results, but androgens or antiestrogens may be helpful when patients are not surgical candidates. Castration continues to be the initial approach, with adrenalectomy or hypophysectomy reserved for promising candidates. In postmenopausal women the initial choice is estrogens. The exceptions are those patients with metastases limited to bone, when androgens excel because of an equivalent objective response and superior subjective and metabolic effects. Patients who respond to estrogens and then progress are observed for a rebound regression following the discontinuation of estrogen therapy. Whereas some who do not respond to androgens will respond to estrogens, the converse does not appear to be true (Kennedy, 1974). Currently progestins are the secondary hormonal agent of choice in postmenopausal women, but they may be displaced by antiestrogens as more data become available. In general, if a patient's tumor lacks estrogen receptors or the patient fails to respond to an adequate trial of endocrine or hormonal therapy, one should proceed directly to cytotoxic chemotherapy. A suggested plan for the integration of endocrine with hormonal therapy and both with other forms of palliation is diagrammed at the end of Chapter 12.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000315:Adrenalectomy; D000328:Adult; D000368:Aged; D000616:Aminoglutethimide / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000628:therapy*; D002369:Castration; D004702:Endocrine Glands / Q000601:surgery*; D045166:Estradiol Congeners / Q000627:therapeutic use; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005260:Female; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D007016:Hypophysectomy; D008875:Middle Aged; D009376:Neoplasms, Hormone-Dependent / Q000628:therapy*; D010053:Ovary / Q000528:radiation effects; D045167:Progesterone Congeners / Q000627:therapeutic use; D045165:Testosterone Congeners / Q000627:therapeutic use; D013963:Thyroid Hormones / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000970:Antineoplastic Agents; D045166:Estradiol Congeners; D004965:Estrogen Antagonists; D006728:Hormones; D045167:Progesterone Congeners; D045165:Testosterone Congeners; D013963:Thyroid Hormones; D000616:Aminoglutethimide